due
errorpron
natur
rnadepend
rnapolymeras
rdrp
rna
viru
replic
character
high
mutat
rate
result
increas
genet
divers
progeni
virus
domingo
et
al
divers
util
viru
evad
escap
immun
system
well
adapt
new
host
maintain
correct
amount
viru
divers
mutat
per
genom
nebot
et
al
utmost
import
rna
viru
surviv
within
host
transmiss
especi
true
arbovirus
arthropod
born
virus
util
two
distinct
host
complet
transmiss
cycl
mutat
rate
rna
viru
high
unfit
progeni
produc
due
increas
number
mutat
deleteri
chanc
result
substanti
decreas
viabl
genom
possibl
extinct
viral
popul
due
error
catastroph
manrubia
et
al
convers
mutat
rate
low
littl
variat
produc
viru
popul
becom
clonal
less
abl
adapt
divers
environ
scenario
reduc
overal
fit
viru
lead
extinct
et
al
predict
lack
fit
high
lowfidel
replic
demonstr
experiment
number
virus
includ
polioviru
pv
pfeiffer
kirkegaard
vignuzzi
et
al
chikungunya
viru
chikv
coffey
et
al
rozengagnon
et
al
west
nile
viru
van
slyke
et
al
st
loui
enceph
viru
griesem
et
al
human
enteroviru
sadeghipour
mcminn
sadeghipour
et
al
meng
kwang
foot
mouth
diseas
viru
aria
et
al
zeng
et
al
xie
et
al
sar
cov
eckerl
et
al
graham
et
al
graepel
et
al
influenza
viru
cheung
et
al
pauli
et
al
noroviru
aria
et
al
coxsacki
b
viru
et
al
levi
et
al
mcdonald
et
al
virus
subject
treatment
nucleosid
analog
ribavirin
fluorouracil
increas
mutat
rate
lead
viru
extinct
insert
mutat
found
chang
fidel
virus
viru
popul
circumv
extinct
develop
resist
nucleosid
analog
sometim
develop
mutat
rdrp
either
increas
high
fidel
decreas
low
fidelityhypermut
rdrp
fidel
ie
rdrp
errorr
compar
unpassag
wildtyp
wt
virus
fidel
mutant
similar
growth
kinet
vitro
attenu
vivo
due
alter
divers
produc
replic
hamper
abil
viru
overcom
bottleneck
host
pfeiffer
kirkegaard
vignuzzi
et
al
alphaviru
genu
famili
togavirida
contain
number
import
arbovirus
distribut
worldwid
alphavirus
classifi
either
old
world
new
world
virus
depend
distribut
venezuelan
equin
enceph
viru
veev
new
world
encephalit
alphaviru
circul
continu
enzoot
cycl
forest
swamp
northern
south
america
central
america
mexico
typic
rodent
mosquito
spillov
cycl
believ
caus
ten
thousand
deadend
human
infect
annual
aguilar
et
al
period
viru
emerg
caus
epizoot
cycl
equid
also
spill
human
sometim
result
hundr
thousand
infect
sudia
et
al
wang
et
al
brault
et
al
weaver
et
al
anishchenko
et
al
prior
equin
epizoot
involv
high
fatal
rate
frequent
record
veevendem
area
sinc
hors
remain
import
compon
local
agricultur
economi
within
region
veev
major
impact
econom
output
atrisk
area
walton
grayson
recent
outbreak
venezuela
mexico
demonstr
abil
veev
reemerg
period
enzoot
nich
ricohess
et
al
weaver
et
al
oberst
et
al
earlier
outbreak
spread
far
north
texa
lord
sudia
et
al
independ
natur
cycl
infect
great
concern
use
veev
biolog
weapon
due
high
infect
via
aerosol
rout
address
threat
multipl
vaccin
develop
protect
veev
infect
first
human
vaccin
describ
vee
produc
follow
serial
passag
trinidad
donkey
veev
strain
subtyp
iab
guinea
pig
heart
cell
berg
et
al
sequenc
reveal
eleven
nucleotid
chang
attenu
attribut
mutat
one
utr
untransl
region
one
glycoprotein
gene
kinney
et
al
relianc
two
point
mutat
attenu
increas
potenti
revers
vaccin
well
instabl
manufactur
concern
support
passag
infant
mice
revert
littl
three
intracrani
passag
mckinney
et
al
retent
mosquito
infect
add
anoth
safeti
concern
transmiss
vaccine
human
equid
isol
wildcaught
mosquito
equin
vaccin
campaign
underscor
risk
pedersen
et
al
due
concern
well
incomplet
immunogen
mckinney
et
al
alevizato
et
al
engler
et
al
approv
equid
maintain
investig
new
drug
statu
atrisk
militari
laboratori
personnel
presenc
high
mutat
rate
thought
one
reason
persist
rna
virus
environ
howev
high
mutat
rate
also
implic
liveattenu
vaccin
lav
typic
gener
longliv
immun
costeffect
lav
replic
potenti
restor
virul
wt
phenotyp
via
one
revers
pseudorevers
event
lead
safeti
concern
possibl
advers
event
follow
immun
rouken
visser
howev
increas
natur
mutat
rate
also
hypothes
decreas
abil
viru
success
revert
pseudorevert
muller
ratchet
muller
chao
accumul
deleteri
mutat
asexu
popul
eg
virus
replic
absenc
effici
recombin
addit
deleteri
mutat
also
impair
abil
fitter
virus
replic
increas
popul
duart
et
al
et
al
et
al
thu
rna
viru
error
rate
fine
tune
allow
optim
viru
popul
health
also
allow
product
mutat
key
adapt
new
host
environ
present
studi
design
determin
whether
mutat
rdrp
alter
viru
fidel
ie
increas
mutat
spectrum
attenu
viru
without
sacrif
vaccin
stabil
immunogen
discov
rdrp
mutat
confer
hypermut
phenotyp
addit
variant
four
mutat
rdrp
found
evid
chang
divers
one
cell
cultur
passag
share
mani
characterist
common
lowfidel
mutant
mutant
result
increas
phenotyp
stabil
compar
wt
viru
well
increas
immunogen
protect
mous
model
identifi
mutat
rdrp
gene
associ
chang
fidel
rescu
infecti
clone
use
initi
serial
vero
cell
passag
duplic
presenc
ribavirin
flurouracil
azacytidin
aza
virus
titer
use
plaqu
assay
follow
passag
dilut
moi
plaqu
form
unit
pfu
cell
subsequ
passag
follow
passag
rdrp
gene
sequenc
three
mutat
identifi
passag
locat
end
rdrp
gene
mutat
result
amino
acid
chang
mutat
result
amino
acid
chang
mutat
result
amino
acid
chang
amino
acid
number
refer
residu
three
mutat
identifi
follow
passag
clone
backbon
conjunct
high
fidel
mutat
previous
identifi
relat
alphaviru
chikv
correspond
posit
coffey
et
al
six
mutant
creat
fig
four
individu
mutant
two
multipl
mutat
mutant
includ
mutant
includ
clone
rescu
electropor
babi
hamster
kidney
bhk
cell
titer
use
standard
plaqu
assay
vero
cell
beati
et
al
rescu
mutant
viabl
produc
pfuml
follow
electropor
data
shown
mutant
includ
amino
acid
chang
rdrp
veev
virus
subject
standard
replic
curv
vero
cell
fig
mutant
show
signific
differ
repeat
measur
anova
sinc
vero
cell
interferondefici
use
human
embryon
kidney
hek
cell
examin
effect
interferon
replic
fidelityalt
virus
mutant
mutant
subject
onestep
replic
curv
fig
vero
cell
signific
differ
observ
virus
parent
confirm
abil
rdrp
mutat
confer
resist
treatment
fig
vero
cell
treat
infect
parent
rdrp
mutant
use
moi
repeat
measur
anova
found
signific
differ
rdrp
mutant
parent
vero
cell
treat
howev
treatment
higher
concentr
caus
titer
singl
rdrp
mutant
drop
compar
parent
demonstr
increas
sensit
treatment
note
significantli
differ
parent
high
concentr
p
treatment
p
treatment
slightli
resist
titer
significantli
reduc
compar
parent
cell
treat
p
resist
treatment
singl
mutant
titer
significantli
reduc
compar
parent
treatment
p
p
other
due
increas
sensit
mutant
unlik
singl
mutat
caus
resist
observ
initi
fidel
mutant
select
unlik
singl
rdrp
mutant
gener
similar
slightli
higher
viru
titer
compar
parent
suggest
increas
resist
treatment
titer
significantli
higher
treatment
p
respect
titer
also
significantli
higher
treatment
p
determin
rdrp
mutant
react
similarli
upon
exposur
anoth
nucleosid
analog
rdrp
mutant
expos
variou
concentr
ribavirin
fig
signific
differ
observ
except
mutant
display
increas
sensit
p
p
assess
virul
individu
mutant
inject
intracrani
mice
titer
ca
pfu
backtit
rang
per
dose
mice
weigh
daili
time
death
record
fig
mutant
significantli
virul
parent
viru
anim
succumb
day
compar
mice
began
succumb
day
p
kaplanmei
test
mean
time
death
parent
mutant
except
day
infect
wherea
show
mean
time
death
day
fidel
mutant
impair
abil
overcom
host
bottleneck
result
reduc
mortal
titer
certain
organ
pfeiffer
kirkegaard
vignuzzi
et
al
graham
et
al
test
individu
mutant
inject
subcutan
mice
measur
abil
caus
mortal
backtit
rang
per
dose
exhibit
significantli
reduc
mortal
reflect
surviv
kaplanmei
test
p
inject
subcutan
compar
origin
compar
intracrani
inject
mice
fig
remain
mutant
caus
similar
mortal
origin
suggest
chang
abil
travers
bottleneck
caus
fatal
diseas
examin
differ
host
arboviru
transmiss
cycl
alter
viru
divers
well
mutant
passag
use
primat
vero
mosquito
cell
compar
parent
viru
fig
rdrp
mutant
chosen
analysi
like
alter
fidel
measur
preliminari
illumina
sequenc
analysi
measur
divers
one
replic
rdrp
mutant
data
shown
well
phenotyp
test
examin
fig
illumina
sequenc
show
mutant
produc
significantli
higher
amount
genet
divers
parent
independ
cell
type
use
fig
along
previous
discuss
result
indic
mutant
lowfidel
variant
interestingli
mutant
demonstr
signific
increas
decreas
divers
compar
cell
type
signific
effect
viru
divers
least
one
passag
number
nucleotid
posit
contain
divers
examin
fig
mutant
trend
toward
produc
increas
number
posit
divers
mutant
look
much
like
parent
lastli
appear
resist
one
nucleosid
analog
fig
e
import
determin
resist
due
alter
type
mutat
made
rdrp
mutant
fig
inde
produc
much
fewer
uc
mutat
uracil
analog
ribavirin
explain
differ
nucleosid
analog
suscept
examin
peak
divers
across
viru
genom
hotspot
conserv
parent
viru
rdrp
mutant
fig
supplementari
fig
includ
aspglu
metstop
minu
strand
valgli
alaasp
minu
strand
argser
parent
reduc
extent
produc
divers
hotspot
gener
differ
posit
consist
alav
valleu
ala
minu
strand
synonym
hotspot
val
synonym
alagli
alagli
ala
minu
sens
synonym
asn
synonym
addit
signific
differ
divers
differ
cell
type
use
fig
appear
increas
number
divers
hotspot
cell
cell
type
immunogen
mutant
test
adult
murin
model
previous
use
test
efficaci
guerboi
et
al
adult
mice
week
age
vaccin
pfu
volum
via
subcutan
rout
anim
bled
day
vaccin
weigh
daili
week
day
fig
anim
exhibit
weight
loss
viremia
sporad
signific
differ
among
virus
repeat
measur
anova
tabl
four
week
postvaccin
anim
bled
assay
neutral
antibodi
titer
fig
vaccin
mice
exhibit
strong
immun
respons
determin
plaqu
reduct
neutral
test
mutant
produc
significantli
higher
mean
neutral
antibodi
titer
compar
repeat
measur
anova
p
respect
follow
challeng
week
postvaccin
veev
subtyp
ic
strain
use
previous
similar
experi
guerboi
et
al
rossi
et
al
anim
weigh
daili
monitor
surviv
fig
vaccin
anim
show
complet
protect
weight
loss
death
wherea
shamvaccin
anim
succumb
day
postchalleng
identif
virus
potenti
fidel
mutant
import
determin
virus
consist
less
virul
infant
mice
subject
popul
bottleneck
especi
import
confirm
mutant
identif
lowfidel
mutant
might
make
strain
less
phenotyp
stabl
test
clone
transcrib
independ
duplic
construct
rescu
use
bhk
cell
produc
pfuml
follow
electropor
measur
virul
mice
inject
intracrani
subcutan
pfu
use
rescu
virus
fig
intracrani
surviv
curv
fig
similar
fig
mice
succumb
day
postinfect
backtit
inocula
rang
pfu
per
dose
depend
replic
group
slightli
less
virul
parent
suggest
rdrp
mutat
alter
virul
administ
intracrani
signific
differ
lethal
observ
fig
like
depend
mutant
spectrum
produc
postelectropor
due
host
variat
subcutan
surviv
curv
fig
significantli
differ
compar
fig
instead
half
mutant
surviv
subcutan
inocul
individu
succumb
day
postinfect
inoculum
back
titer
rang
pfu
per
dose
although
mice
succumb
variat
replic
exampl
one
replic
surviv
averag
day
replic
surviv
averag
day
intracrani
surviv
curv
result
suggest
differ
postelectropor
minor
popul
result
variat
degre
attenu
lowfidel
virus
confirm
fidelityalt
mutat
revert
upon
repeat
replic
subject
five
passag
vero
cell
sanger
sequenc
rdrp
reveal
mutat
data
shown
rdrp
mutant
also
subject
serial
intracrani
passag
infant
mice
determin
compensatori
mutat
accumul
vivo
passag
viru
inject
subcutan
mice
assess
chang
virul
occur
passag
gain
virul
passag
compar
unpassag
counterpart
shown
fig
kaplanmei
test
p
fig
point
mutant
reach
virul
equival
origin
unpassag
signific
differ
time
death
interestingli
signific
chang
virul
occur
passag
virus
indic
reach
virul
equival
unpassag
unabl
increas
virul
past
point
addit
statist
signific
mice
inocul
passag
surviv
week
longer
mice
inocul
passag
suggest
addit
passag
may
result
decreas
fit
construct
illumina
sequenc
follow
mous
brain
passag
show
increas
divers
fig
suggest
may
actual
low
fidel
multipl
growth
cycl
may
requir
truli
assess
fidel
chang
curious
divers
hotspot
increas
hotspot
observ
one
cell
cultur
passag
greatli
reduc
passag
virus
fig
even
though
differ
electropor
stock
use
infant
mice
passag
still
exhibit
fewer
uc
mutat
fig
supplementari
fig
suggest
stabl
phenotyp
two
rdrp
mutant
although
produc
divers
parent
fewer
revert
occur
mutat
requir
attenu
fig
kinney
et
al
due
posit
utr
attenu
mutat
coverag
low
assess
true
differ
potenti
site
also
revert
read
contain
revert
mutat
viru
follow
passag
mous
brain
sanger
sequenc
use
identifi
sever
snp
tabl
produc
two
snp
follow
passag
consensu
sequenc
chang
none
snp
revert
mutat
caus
attenu
insert
rdrp
mutat
addit
converg
mutat
found
passag
seri
infecti
diseas
transmit
arthropod
vector
difficult
control
protect
popul
via
vaccin
tend
effect
tri
control
erad
vector
popul
although
lav
tend
costeffect
immunogen
lav
signific
achil
heel
potenti
revers
wt
virul
risk
particularli
acut
rna
virus
replic
without
proofread
result
increas
abil
revert
wt
sequenc
restor
virul
via
compensatori
mutat
pseudorevers
howev
alter
viru
fidel
theoret
overcom
major
drawback
approach
examin
fidel
mutant
pv
lowfidel
exon
mutant
sarscov
graham
et
al
vignuzzi
et
al
high
fidel
pv
vignuzzi
et
al
sarscov
exon
graham
et
al
mutant
demonstr
increas
immunogen
improv
safeti
profil
compar
parent
virus
observ
low
fidel
polioviru
korboukh
et
al
howev
fidel
mutant
gener
use
wt
viru
strain
unlik
suffici
attenu
vaccin
use
hypothes
increas
attenu
liveattenu
rna
viru
vaccin
alter
rdrp
fidel
would
improv
safeti
efficaci
address
valid
seri
lowfidel
mutat
model
system
use
veev
vaccin
strain
determin
affect
stabil
attenu
serial
passag
identifi
three
mutat
rdrp
valid
show
three
mutat
requir
decreas
viru
replic
fidel
addit
identifi
mutant
act
much
like
show
differ
divers
one
cell
cultur
passag
present
atom
resolut
structur
alphaviru
rdrp
limit
understand
mechan
fidel
alter
howev
mutat
mutant
end
gene
similar
placement
pv
high
fidel
low
fidel
substitut
peripheri
rdrp
protein
rather
near
activ
site
pfeiffer
kirkegaard
campagnola
et
al
korboukh
et
al
pv
presenc
mutat
significantli
alter
structur
polymeras
decreas
incorpor
rate
new
nucleotid
arnold
et
al
marcott
et
al
fact
current
theori
substitut
simpli
stabil
polymeras
rather
alter
activ
site
altern
low
fidel
pv
decreas
fidel
favor
open
state
rdrp
decreas
durat
fidel
checkpoint
thu
increas
likelihood
ntp
misincorpor
moustafa
et
al
presenc
lowfidel
mutat
outsid
predict
activ
domain
gene
suggest
similar
mechan
confirm
requir
atom
resolut
structur
two
manner
lowfidel
mutant
isol
either
mutat
residu
found
alter
fidel
virus
passag
viru
presenc
nucleosid
analog
latter
aria
et
al
pauli
et
al
van
slyke
et
al
three
lowfidel
mutant
identifi
resist
nucleosid
analog
use
passag
sensit
nucleosid
analog
concord
lowfidel
mutant
exhibit
higher
fidel
specif
mutat
select
nucleosid
analog
lower
fidel
mutat
fidel
mutant
appear
act
similarli
lowfidel
virus
resist
fluorouracil
ribavirin
examin
mutat
frequenc
differ
mutat
fidel
mutant
produc
much
lower
amount
u
c
transit
mutat
would
one
mutat
expect
select
fu
passag
also
may
explain
mutant
resist
fu
use
moder
amount
nucleosid
analog
increas
suscept
higher
concentr
differ
uracil
mutat
frequenc
clearli
lowfidel
mutant
evidenc
phenotyp
test
well
increas
genet
divers
observ
use
illumina
sequenc
mutant
exhibit
phenotyp
similar
alter
fidel
mutant
signific
differ
viru
divers
compar
parent
one
cell
cultur
passag
howev
may
actual
lowfidel
variant
suggest
increas
divers
occur
vivo
passag
exhibit
gain
divers
nearli
ident
perhap
mutat
coffey
et
al
high
fidel
chikv
mutat
offer
addit
effect
initi
increas
viru
divers
wt
viru
exert
addit
attenu
via
unknown
mechan
howev
appear
mutat
exert
less
effect
multipl
viru
replic
cycl
result
increas
viru
divers
compar
parent
passag
vivo
altern
could
cumul
effect
mutat
alter
abil
viru
explor
benefici
sequenc
space
viru
replic
lead
muller
ratchet
decreas
viru
health
inde
may
explain
mutant
initi
exhibit
gain
virul
vivo
passag
later
becam
attenu
would
interest
continu
passag
mutant
determin
mutat
threshold
eventu
cross
lead
error
catastroph
viru
extinct
hypothesi
valid
construct
like
safer
lav
candid
mutant
inde
mixtur
two
hypothes
might
explain
observ
result
also
interest
substitut
increas
replic
fidel
chikv
affect
fidel
although
attenu
infant
mous
model
find
opposit
outcom
sindbi
viru
exhibit
lowfidel
featur
lowfidel
chikv
mutat
insert
rozengagnon
et
al
howev
sindbi
viru
close
relat
chikv
veev
may
explain
effect
transfer
even
though
residu
highli
conserv
among
alphavirus
coffey
et
al
illumina
sequenc
uncov
mani
noteworthi
effect
rdrp
mutant
growth
vitro
particular
divers
peak
identifi
greatli
decreas
rdrp
mutant
glycoprotein
respons
uncoat
viru
particl
escap
genom
cytosol
substitut
chikv
glycoprotein
found
increas
vector
infect
transmiss
tsetsarkin
et
al
vazeil
et
al
divers
region
may
import
increas
vector
fit
andor
host
jump
total
genom
divers
analyz
construct
signific
differ
divers
compar
cell
type
contradict
lowfidel
chikv
mutant
show
increas
divers
vertebr
cell
mosquito
cell
rozengagnon
et
al
howev
signific
differ
observ
overal
divers
cell
type
produc
much
higher
peak
divers
cell
observ
cell
type
virus
intrigu
hypothes
mosquito
driver
divers
like
due
sequenc
specif
mosquito
antivir
rnai
respons
ie
sirna
although
demonstr
west
nile
viru
brackney
et
al
grubaugh
et
al
hypothesi
appear
explain
increas
divers
observ
passag
cell
lack
function
sirna
respons
addit
increas
hotspot
observ
cell
produc
antivir
sirna
work
need
determin
divers
hotspot
correspond
small
rna
target
mosquito
cell
examin
effect
host
immun
respons
viru
popul
previou
studi
shown
high
fidel
pv
mutat
caus
attenu
mous
model
reduc
dissemin
central
nervou
system
pfeiffer
kirkegaard
vignuzzi
et
al
test
mutant
lethal
mous
model
rdrp
mutant
initi
display
equival
virul
parent
inject
singl
tissu
caus
lethal
damag
brain
reduc
virul
inject
via
multitissu
model
subcutan
howev
experi
repeat
viru
rescu
differ
electropor
pool
mutant
display
greatli
increas
virul
compar
initi
subcutan
outcom
suggest
minor
variant
randomli
gener
transcript
preced
electropor
larg
effect
overal
viru
popul
health
thu
virul
importantli
alway
equal
virul
inject
subcutan
compar
rdrp
mutant
lethal
adult
mous
model
would
interest
determin
mutant
consist
delay
andor
decreas
dissemin
compar
wt
viru
would
allow
greater
understand
lowfidel
vaccin
would
oper
fulli
immunocompet
host
establish
differ
pool
viru
may
exhibit
differ
degre
virul
becam
import
test
whether
mutant
would
remain
attenu
allow
experi
multipl
growth
cycl
perhap
counterintuit
hyper
mutat
variant
undergo
initi
increas
virul
vivo
passag
revert
level
virul
unpassag
like
due
increas
amount
unfit
virion
eg
defect
interf
di
particl
hamper
wt
viru
virul
well
inabl
mutant
revert
insert
rdrp
mutat
passag
result
viru
similar
passag
data
except
viru
decreas
virul
much
infant
mice
abl
surviv
extra
day
passag
data
demonstr
mutant
exhibit
decreas
risk
revers
wt
virul
compar
parent
studi
design
evalu
effect
rdrp
mutat
decreas
fidel
vaccin
mutant
put
standard
challeng
model
previous
use
differ
veev
vaccin
guerboi
et
al
rossi
et
al
mice
show
advers
effect
vaccin
viremia
consist
expect
mice
protect
lethal
challeng
addit
mutant
induc
higher
antibodi
titer
current
hypothesi
observ
lowfidel
rdrp
creat
increas
number
di
viru
particl
well
known
strong
immun
stimul
dimmock
kennedi
et
al
tapia
et
al
sun
et
al
veev
first
amplifi
drain
lymph
node
macdonald
johnston
presenc
di
particl
may
restrict
dissemin
drain
lymph
node
allow
greater
opportun
antigen
present
therefor
increas
immun
respons
need
explor
futur
work
demonstr
presenc
lowfidel
mutat
lav
result
reduc
virul
infant
mous
model
increas
immunogen
adult
mous
model
desir
properti
lav
howev
also
observ
differ
outcom
lowfidel
mutant
attenu
vivo
differ
pool
viru
stock
use
suggest
lowfidel
viru
popul
might
initi
stabl
demonstr
great
need
understand
role
minor
variant
play
phenotyp
chang
vaccin
develop
chang
mutant
spectrum
may
significantli
alter
phenotyp
vaccin
howev
passag
result
impli
viru
popul
stabil
multipl
growth
cycl
lowfidel
rna
viru
vaccin
may
requir
passag
ensur
consist
vaccin
phenotyp
overal
studi
demonstr
lowfidel
mutat
may
potenti
tool
develop
initi
phenotyp
instabl
observ
post
electropor
suggest
may
current
viabl
strategi
lav
develop
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
protocol
approv
institut
anim
care
use
committe
univers
texa
medic
branch
vero
african
green
monkey
kidney
bhk
cell
obtain
american
type
cell
collect
bethesda
md
maintain
dulbecco
minim
essenti
medium
dmem
supplement
fetal
bovin
serum
fb
penicillin
streptomycin
penstrep
uml
incub
cell
maintain
dmem
supplement
fb
minim
essenti
medium
nonessenti
amino
acid
trypos
phosphat
broth
penstrep
uml
incub
cell
maintain
mitsuhashi
maramorosch
media
supplement
fb
sodium
bicarbon
penstrep
uml
incub
virus
rescu
infecti
clone
describ
previous
without
passag
smith
et
al
virus
passag
vero
cell
unless
otherwis
state
titer
viru
determin
standard
plaqu
assay
use
vero
cell
beati
et
al
parent
passag
presenc
mutagen
ribavirin
sigma
aldrich
st
loui
mo
fluorouracil
sigma
aldrich
azacytidin
sigma
aldrich
concentr
mm
respect
cell
pretreat
h
prior
infect
mutagen
duplic
infect
multipl
infect
moi
pfucel
follow
incub
period
cell
fed
dmem
supplement
fb
penstrep
uml
well
mutagen
origin
pretreat
supernat
harvest
day
postinfect
store
supplement
fb
viral
titer
determin
standard
plaqu
assay
beati
et
al
virus
sequenc
use
sanger
sequenc
passag
determin
mutat
occur
rdrp
six
subclon
contain
mutat
identifi
rdrp
highfidel
chikv
rdrp
creat
joiningpcr
cdna
fragment
genom
use
design
primer
sequenc
construct
verifi
prior
clone
genom
infecti
clone
backbon
virus
rescu
electropor
bhk
cell
describ
previous
green
et
al
ensur
insert
mutat
interfer
viral
replic
standard
replic
curv
conduct
cell
infect
moi
vero
plate
incub
h
wash
twice
phosphat
buffer
salin
pb
overlaid
ml
dmem
supplement
fb
penstrep
uml
viru
harvest
remov
entireti
medium
replac
ml
fresh
medium
harvest
viru
supplement
fb
final
concentr
clarifi
centrifug
rpm
min
supernat
remov
store
viral
titer
determin
standard
plaqu
assay
beati
et
al
rescu
virus
passag
five
time
vero
cell
ensur
genet
stabil
virus
harvest
day
postinfect
dilut
infect
vero
cell
subsequ
passag
follow
passag
viral
suspens
place
buffer
avl
qiagen
valencia
ca
rna
extract
use
column
method
per
manufactur
protocol
cdna
produc
use
superscript
iii
first
round
synthesi
kit
invitrogen
carlsbad
ca
follow
manufactur
instruct
cdna
amplifi
sequenc
use
phusion
enzym
neb
madison
wi
volum
follow
manufactur
instruct
use
primer
set
cover
rdrp
region
genom
primer
avail
upon
request
product
sequenc
abi
sequenc
abi
rescu
virus
test
suscept
ribavirin
triplic
cell
pretreat
ribavirin
h
cell
infect
moi
rdrp
mutant
well
medium
contain
pretreat
amount
ribavirin
ad
infect
cell
postinfect
viru
harvest
postinfect
titrat
duplic
use
standard
plaqu
assay
studi
virul
attenu
mice
charl
river
wilmington
inocul
intracrani
ic
pfu
viru
volum
subcutan
sc
pfu
volum
anim
weigh
daili
week
monitor
surviv
anoth
experi
mice
vaccin
sc
origin
viru
one
rdrp
mutant
pfu
volum
pb
unvaccin
control
n
per
cohort
sixweek
postvaccin
anim
challeng
sc
pfu
wt
epidem
veev
strain
et
al
daili
monitor
sign
ill
surviv
weight
loss
blood
sampl
collect
altern
cage
vaccin
mice
day
postvaccin
day
postchalleng
viremia
detect
well
week
postvaccin
antibodi
measur
prnt
assess
genet
phenotyp
vivo
stabil
rdrp
mutant
subject
serial
ic
passag
sixdayold
mice
dose
ca
pfu
volum
per
anim
anim
euthan
postinocul
brain
harvest
homogen
determin
viral
titer
standard
plaqu
assay
beati
et
al
homogen
brain
dilut
produc
inoculum
dose
use
initi
subsequ
passag
virul
mous
passag
virus
compar
parent
strain
inocul
mice
sc
pfu
describ
earlier
stabil
genom
sequenc
assess
rtpcr
rna
extract
mous
passag
virus
sequenc
use
illumina
sanger
sequenc
respect
viral
rna
cell
cultur
extract
fragment
incub
min
fragment
buffer
illumina
san
diego
ca
first
second
strand
synthesi
adapt
ligat
amplif
librari
perform
use
illumina
truseq
rna
sampl
prepar
kit
per
manufactur
protocol
viru
isol
anim
pcr
first
done
use
sequencespecif
primer
tile
across
veev
genom
provid
amplifi
product
kb
size
use
librari
gener
product
fragment
use
transposon
adapt
ligat
amplif
librari
perform
use
illumina
truseq
rna
sampl
prepar
kit
condit
describ
manufactur
illumina
san
diego
ca
sampl
track
use
index
tag
incorpor
adapt
defin
manufactur
qualiti
sampledataset
assess
use
fastqc
hoffmann
et
al
pairedend
read
merg
sampl
filter
exclud
read
unknown
charact
anyth
c
g
low
qualiti
qualiti
score
high
qualiti
read
use
analysi
addit
first
base
read
trim
due
nucleotid
bia
analysi
perform
use
veev
strain
complet
genom
genbank
access
r
kinney
et
al
analyz
variant
hotspot
sampl
run
novel
rare
variant
pipelin
avail
upon
request
pipelin
first
map
read
refer
veev
genom
perfect
match
unmap
read
remap
mismatch
ad
final
map
base
long
read
use
analys
valid
viral
sequenc
host
sequenc
analysi
longest
subsequ
share
explicitli
mismatch
allow
longest
similar
mismatch
allow
viral
host
genom
divers
per
posit
viral
genom
calcul
take
ratio
read
map
mismatch
read
map
posit
posit
number
read
map
mismatch
higher
perfectli
map
read
coverag
exclud
divers
calcul
mutat
frequenc
per
sampl
calcul
sum
per
posit
divers
normal
number
posit
divers
calcul
posit
nonzero
mutat
frequenc
consid
variant
posit
graphpad
prism
use
perform
statist
test
describ
text
